Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxybutynin chloride · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | Oxybutynin chloride 15 mg once daily for 12 weeks |
| 002 | PLACEBO_COMPARATOR | Placebo Once daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Once daily for 12 weeks |
| Oxybutynin chloride | DRUG | 15 mg once daily for 12 weeks |
Inclusion Criteria: * Patients must be in good health * Must be naturally postmenopausal and have not experienced menses for at least 6 months prior to the start of the study * Must have serum FSH levels \> 40 mIU/mL * Must average seven or more moderate to severe hot flushes with sweating per day,...
Oxybutynin chloride is being studied for the treatment of vasomotor symptoms, commonly known as hot flashes, in healthy post-menopausal women. It is an investigational small molecule in Phase 2 clinical development for this indication, and it has not been approved for this use.
Oxybutynin chloride is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research to evaluate the drug's effects on menopausal symptoms.
Oxybutynin chloride is in Phase 2 clinical development for the treatment of vasomotor symptoms in post-menopausal women. It is an investigational drug, meaning it has not yet been approved by regulatory authorities for this indication.
Oxybutynin chloride has one completed clinical trial, identified as NCT00990886. This Phase 2 study evaluated the effect of extended-release oxybutynin chloride on vasomotor symptoms in healthy post-menopausal women, enrolling 148 participants.
Oxybutynin chloride is an anticholinergic agent that works by blocking the action of acetylcholine on muscarinic receptors. This mechanism is thought to help reduce the frequency and severity of hot flashes in post-menopausal women.